MiniMed Group, a Medtronic spin-off, is rated a buy with an FY 2027 price target of $19, implying 15% upside. MMED's double-digit revenue growth is driven by strong international adoption, expanding CGM attach rates, and timely product launches ahead of schedule. Despite gross margin compression and widened net losses in FY 2026, robust liquidity from IPO proceeds supports ongoing product rollouts and operational improvements.
MiniMed Group NASDAQ: MMED reported record fiscal 2026 revenue and outlined a slate of product launches it said will support faster growth in fiscal 2027, as management held the company's first earnings call as a standalone public company following its March IPO.
MiniMed study results show MiniMed 780G delivering consistent glycemic outcomes across sensors, reinforcing SmartGuard's strength.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Chilton Investment Chilton Investment Co Inc. | 55,500 | $828,060 | $950,715 | $122,655 | 14.81% |
Point72 Asset Management LP Point72 Asset Management LP | 1.14M | $17.01M | $19.29M | $2.28M | 13.4% |
Regan O'Neill Burkehill Global Management LP | 300,000 | $4.48M | $5.11M | $631,830 | 14.12% |
Taro Kuriyama Axq Capita LLP | 19,165 | $285,942 | $323,121.9 | $37,179.9 | 13% |
Lydia Moore MRP Capital Investments LLC | 90 | $1,343 | $1,522.8 | $179.8 | 13.39% |
| Diversified Consumer Services Industry | Consumer Discretionary Sector | Que Thanh Dallara CEO | NASDAQ (NMS) Exchange | 60365F109 CUSIP |
| US Country | 8,000 Employees | - Last Dividend | - Last Split | - IPO Date |
MiniMed Group, Inc. specializes in the development, manufacturing, and marketing of innovative medical devices designed specifically for diabetes management. Established in 1983 by Alfred E. Mann, the company is headquartered in Northridge, California. MiniMed Group focuses on creating solutions that empower individuals with diabetes and their healthcare providers to effectively monitor and regulate blood glucose levels, significantly improving patient outcomes and quality of life.